Mitchell Kapoor
Stock Analyst at H.C. Wainwright
(4.51)
# 905
Out of 4,792 analysts
790
Total ratings
42.3%
Success rate
10.8%
Average return
Main Sectors:
Stocks Rated by Mitchell Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Reiterated: Buy | $45 | $12.20 | +268.85% | 26 | Sep 11, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $344 | $261.23 | +31.68% | 3 | Sep 10, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 | $65.51 | -8.41% | 16 | Sep 10, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Reiterated: Buy | kr 575.00 | kr 437.20 | +31.52% | 9 | Sep 10, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $45 → $30 | $23.54 | +27.44% | 38 | Sep 10, 2026 | |
| EVMN Evommune | Reiterated: Hold | n/a | $10.56 | - | 9 | Sep 9, 2026 | |
| GENB Generate Biomedicines | Reiterated: Buy | $30 | $15.39 | +94.93% | 5 | Sep 9, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $25 | $11.93 | +109.56% | 17 | Sep 9, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Sell | $5 | $20.52 | -75.63% | 35 | Sep 9, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $115 → $100 | $55.65 | +79.69% | 33 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $19.19 | +238.72% | 64 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 | $107.00 | +7.48% | 61 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $91.65 | +30.93% | 19 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $29.47 | +103.60% | 2 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.00 | - | 38 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $25 → $15 | $9.90 | +51.52% | 25 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $123.28 | +21.67% | 20 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $52.26 | +53.08% | 19 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $13.06 | +14.85% | 24 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $12.85 | +55.64% | 5 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $10.35 | +141.55% | 2 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.94 | +157.73% | 29 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $7.35 | +240.14% | 21 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $65 | $36.12 | +79.96% | 35 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $26.84 | +67.66% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.01 | +248.26% | 5 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $17.18 | +74.62% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $8.43 | +196.56% | 24 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.65 | +88.68% | 10 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $19.46 | - | 9 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $11 | $3.35 | +228.36% | 30 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $10 | $4.36 | +129.36% | 16 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.36 | - | 20 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.84 | +40.85% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.16 | +503.45% | 14 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $5.38 | n/a | 9 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $6.74 | n/a | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.75 | n/a | 26 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0008 | n/a | 16 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $0.822 | n/a | 24 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $5.48 | n/a | 2 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $3.27 | n/a | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.7625 | n/a | 8 | Aug 11, 2023 |
Lyell Immunopharma
Sep 11, 2026
Reiterated: Buy
Price Target: $45
Current: $12.20
Upside: +268.85%
Ascendis Pharma
Sep 10, 2026
Reiterated: Buy
Price Target: $344
Current: $261.23
Upside: +31.68%
BioMarin Pharmaceutical
Sep 10, 2026
Reiterated: Hold
Price Target: $60
Current: $65.51
Upside: -8.41%
Swedish Orphan Biovitrum AB (publ)
Sep 10, 2026
Reiterated: Buy
Price Target: kr 575.00
Current: kr 437.20
Upside: +31.52%
Tyra Biosciences
Sep 10, 2026
Reiterated: Buy
Price Target: $45 → $30
Current: $23.54
Upside: +27.44%
Evommune
Sep 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $10.56
Upside: -
Generate Biomedicines
Sep 9, 2026
Reiterated: Buy
Price Target: $30
Current: $15.39
Upside: +94.93%
Intellia Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $25
Current: $11.93
Upside: +109.56%
Sarepta Therapeutics
Sep 9, 2026
Reiterated: Sell
Price Target: $5
Current: $20.52
Upside: -75.63%
Ionis Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $115 → $100
Current: $55.65
Upside: +79.69%
Sep 4, 2026
Reiterated: Buy
Price Target: $65
Current: $19.19
Upside: +238.72%
Sep 3, 2026
Reiterated: Buy
Price Target: $115
Current: $107.00
Upside: +7.48%
Sep 3, 2026
Reiterated: Buy
Price Target: $120
Current: $91.65
Upside: +30.93%
Sep 3, 2026
Reiterated: Buy
Price Target: $60
Current: $29.47
Upside: +103.60%
Sep 3, 2026
Reiterated: Hold
Price Target: n/a
Current: $17.00
Upside: -
Sep 2, 2026
Upgraded: Buy
Price Target: $25 → $15
Current: $9.90
Upside: +51.52%
Sep 1, 2026
Reiterated: Buy
Price Target: $150
Current: $123.28
Upside: +21.67%
Aug 31, 2026
Reiterated: Buy
Price Target: $80
Current: $52.26
Upside: +53.08%
Aug 21, 2026
Reiterated: Buy
Price Target: $15
Current: $13.06
Upside: +14.85%
Aug 14, 2026
Reiterated: Buy
Price Target: $20
Current: $12.85
Upside: +55.64%
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $10.35
Upside: +141.55%
Aug 13, 2026
Reiterated: Buy
Price Target: $5
Current: $1.94
Upside: +157.73%
Aug 12, 2026
Reiterated: Buy
Price Target: $25
Current: $7.35
Upside: +240.14%
Aug 12, 2026
Reiterated: Buy
Price Target: $70 → $65
Current: $36.12
Upside: +79.96%
Aug 11, 2026
Reiterated: Buy
Price Target: $45
Current: $26.84
Upside: +67.66%
Aug 11, 2026
Reiterated: Buy
Price Target: $7
Current: $2.01
Upside: +248.26%
Aug 7, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $17.18
Upside: +74.62%
Aug 7, 2026
Reiterated: Buy
Price Target: $25
Current: $8.43
Upside: +196.56%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $2.65
Upside: +88.68%
Jul 31, 2026
Reiterated: Hold
Price Target: n/a
Current: $19.46
Upside: -
May 11, 2026
Reiterated: Buy
Price Target: $17 → $11
Current: $3.35
Upside: +228.36%
Jan 13, 2026
Reiterated: Buy
Price Target: $13 → $10
Current: $4.36
Upside: +129.36%
Jan 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.36
Upside: -
Oct 24, 2025
Reiterated: Buy
Price Target: $4
Current: $2.84
Upside: +40.85%
Oct 22, 2025
Reiterated: Buy
Price Target: $7
Current: $1.16
Upside: +503.45%
Aug 19, 2025
Reiterated: Hold
Price Target: $3 → $2
Current: $5.38
Upside: n/a
Aug 11, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $6.74
Upside: n/a
Apr 30, 2025
Rated: Hold
Price Target: n/a
Current: $16.75
Upside: n/a
Apr 4, 2025
Rated: Hold
Price Target: n/a
Current: $0.0008
Upside: n/a
Apr 3, 2025
Reiterated: Buy
Price Target: $9
Current: $0.822
Upside: n/a
Mar 21, 2025
Reiterated: Buy
Price Target: $15
Current: $5.48
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $15
Current: $3.27
Upside: n/a
Aug 11, 2023
Reiterated: Hold
Price Target: n/a
Current: $0.7625
Upside: n/a